4investors | Börsen-News | Adhoc- und Unternehmensnews | Paion

DGAP-News: PAION ANNOUNCES ATTENDANCE AT FOUR UPCOMING CONFERENCES

Bild und Copyright: joker1991 / shutterstock.com.

Bild und Copyright: joker1991 / shutterstock.com.

07.02.2019, 14:00:02 (www.4investors.de - in Kooperation mit DGAP - EQS Group):




DGAP-News: PAION AG / Key word(s): Conference

PAION ANNOUNCES ATTENDANCE AT FOUR UPCOMING CONFERENCES
07.02.2019 / 14:00


The issuer is solely responsible for the content of this announcement.
 

PAION ANNOUNCES ATTENDANCE AT FOUR UPCOMING CONFERENCES

Aachen (Germany), 07 February 2019 - The specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces its participation in four upcoming conferences. PAION representatives will be available for one-on-one meetings at these events.

2019 BIO CEO & Investor Conference
11 - 12 February 2019
New York Marriott Marquis
New York, U.S.https://www.bio.org/events/bio-ceo-investor-conference13th ODDO BHF German Conference
19 - 20 February 2019
The Westin Grand Hotel
Frankfurt am Main, GermanyBio-Europe Spring
25 - 27 March 2019
Messe Wien Exhibition and Congress Center
Vienna, Austriahttps://ebdgroup.knect365.com/bioeurope-spring/

Invest Stuttgart
05 - 06 April 2019
Meet us in hall 4, booth 4D52
Messe Stuttgart
Stuttgart, Germanyhttps://www.messe-stuttgart.de/invest

###

About PAION
PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs for out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside the U.S., PAION is currently focused on the development of remimazolam for general anesthesia. Development of remimazolam for intensive care unit (ICU) sedation is also part of the longer-term life-cycle plan for remimazolam.
PAION's vision is to become an acknowledged "PAIONeer" in sedation and anesthesia. PAION is headquartered in Aachen (Germany) with an additional site in Cambridge (United Kingdom).

PAION Contact
Ralf Penner
Vice President Investor Relations/Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.comwww.paion.com

Disclaimer:

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.












07.02.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
PAION AG

Martinstr. 10-12

52062 Aachen


Germany
Phone:
+49 (0)241-4453-0
Fax:
+49 (0)241-4453-100
E-mail:
info@paion.com
Internet:
www.paion.com
ISIN:
DE000A0B65S3
WKN:
A0B65S
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News
DGAP News Service




773113  07.02.2019 



Exklusiv-Berichte und Interviews aus der 4investors Redaktion:

Aroosh Thillainathan, CEO bei Northern Data, im Interview mit der 4investors-Redaktion.Northern Data: „Die Nachfrage übersteigt unsere Kapazitäten um das Dreißigfache“

4investors-Newsletter

Exklusive Interviews und Analysen für Sie aus der 4investors-Redaktion!

Der Newsletter ist kostenlos. Sie können den Newsletter jederzeit wieder abbestellen. Wir speichern Ihre Mailadresse ausschließlich zum Versand des Newsletters und geben diese nicht weiter! Bitte beachten Sie unsere Datenschutzerklärung.

Weitere DGAP-News von Paion

4investors-News zu Paion

02.04.2020 - Paion: EU-Studie mit Remimazolam erreicht wichtiges Zwischenziel
02.04.2020 - Paion Aktie: Auf diese Marken müssen Trader achten!
27.03.2020 - Paion: Mehr Geduld
26.03.2020 - Paion: Gelingt 2020 der Sprung in die Gewinnzone?
24.03.2020 - Paion Aktie: Das steckt hinter dem Kurssprung
16.03.2020 - Paion Aktie: Diese Entwicklung ist interessant
13.03.2020 - Paion Aktie stabilisiert sich - Vorstand nimmt Stellung zur FDA-News
12.03.2020 - Paion Aktie: Der entscheidende Termin rückt näher!
05.03.2020 - Paion Aktie: Kommt jetzt der Ausbruch?
03.03.2020 - Paion Aktie nimmt Schwung auf: Spekulationen auf FDA-Termin
02.03.2020 - Paion Aktie: Zwischen Corona-Panik und US-Zulassungsentscheidung
27.02.2020 - Paion: Positive Entwicklung in Übersee
28.01.2020 - Paion Aktie: Neuer fairer Wert nach Japan-News
28.01.2020 - Paion Aktie: Was ist hier los?
24.01.2020 - Paion Aktie: Die Situation gewinnt an Spannung und Dramatik
23.01.2020 - Paion: Nächste gute News zu Remimazolam
14.01.2020 - Paion: 2020 bringt schwarze Zahlen
13.01.2020 - Paion Aktie: Wird es jetzt wieder „typisch” für diesen Titel?
08.01.2020 - Paion: Remimazolam-Millionen aus Südkorea
07.01.2020 - Paion Aktie: Fast 40 Prozent Potenzial